Cite
HARVARD Citation
Wilson, W. et al. (2021). Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*. Leukemia & lymphoma. 62 (9), pp. 2094-2106. [Online].